Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

2004 ◽  
Vol 40 (2) ◽  
pp. 205-211 ◽  
Author(s):  
T. Petit ◽  
M. Wilt ◽  
M. Velten ◽  
R. Millon ◽  
J.-F. Rodier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Topoisomerase Ii ◽  
Predictive Markers ◽  
Breast Cancer Patients ◽  
Tumour Grade ◽  
Topoisomerase Ii Alpha ◽  
Ki 67 ◽  
Hormonal Receptors ◽  
Her 2

scholarly journals Gambaran Usia dan Stadium Klinis Pasien Kanker Payudara yang dilakukan Pemeriksaan Imunohistokimia di Rumah Sakit Abdul Wahab Sjahranie pada Tahun 2018

2020 ◽  
Vol 8 (2) ◽  
pp. 126-140
Author(s):  
Ade Yusuf Yulianto ◽  
Hadi Irawiraman ◽  
P.M.T. Mangalindung Ompusunggu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Clinical Stage ◽  
Descriptive Study ◽  
Regional Hospital ◽  
Breast Cancer Patients ◽  
Immunohistochemical Examination ◽  
Ki 67 ◽  
Her 2

ABSTRACKBreast cancer still occupies the highest incidence of all types of malignancies in women. Based on data recorded at Abdul Wahab Sjahrenie Hospital, 200 new cases are found each year. Immunohistochemical profile examination has been used extensively as a basis for classifying breast cancer molecularly. Expression of hormone receptors (ER, PR) and HER-2 found in immunohistochemical examinations are useful for determining therapeutic options that fit the patient's needs. The purpose of this descriptive study was to determine the characteristics of the immunohistochemical profile of breast cancer patients in Abdul Wahab Sjahranie Regional Hospital Samarinda in the January-December 2018 period based on age and clinical stage that had been examined by immunohistochemical examination including the expression of ER PR, Ki-67 and HER2. Method: This study used a cross-sectional descriptive study design by taking secondary data from breast cancer patients who had performed immunohistochemical examinations at Abdul Wahab Sjahranie Regional Hospital Samarinda in the January 2018 - December 2018 period. From 479 breast cancer patients came to Abdul Wahab Regional Hospital Sjahranie Samarinda, only 177 (37.18%) patients did immunohistochemical examinations. Most patients aged 40-49 were 65 patients (36.7%) had breast cancer, the highest clinical stage IIIB with 92 cases (52%), the Ki-67 with severe highest interpretation, range> 30% with 73 patients (41.2%), more positive ER than negative, in 93 patients (52.5%), while negative examination results 84 patients (47.5%). PR is the same as ER, which is 96 patients (54.2%), while negative examination results are 81 patients (45.8%). Most HER-2 results were negative, in 109 patients (61.6%). In this study the highest number of cases of breast cancer patients ranged between the ages of 40-49 years and at least aged 70 years and above. The clinical stage is most often found in stage IIIB (advanced). Ki-67 examination was found most frequently in severe interpretations. Examination of estrogen receptors is found to be most widely in positive interpretation. Positive progesterone tests to be most widely than negative examinations. Her-2 examination was found to be most widely in negative interpretation Keywords: Immunohistochemical examination, Hormone receptors, HER-2, Clinical Stadium

Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime?

2008 ◽  
Vol 44 (18) ◽  
pp. 2791-2798 ◽  
Author(s):  
Angelo Di Leo ◽  
Laura Biganzoli ◽  
Wederson Claudino ◽  
Sara Licitra ◽  
Marta Pestrin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Topoisomerase Ii ◽  
Breast Cancer Patients ◽  
Topoisomerase Ii Alpha

scholarly journals Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Khalid Dafaallah Awadelkarim ◽  
Renato Mariani-Costantini ◽  
Ihsan Osman ◽  
Massimo Costanzo Barberis
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Interquartile Range ◽  
Labeling Index ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Significant Group ◽  
Cancer Subtypes ◽  
Her 2

Ki-67 labeling index has been linked to patient outcome in breast cancer patients. However, very few published reports have examined Ki-67 labeling index in African breast cancer patients. Sixty-two Sudanese breast cancer patients with primary invasive tumors were immunostained for Ki-67, ER, PR, Her-2/neu, CK5/6, and CK17. Ki-67 labeling index ranged from 0% to 50%, with a median of 5% (interquartile range 0–10). Low Ki-67 labeling index (immunostaining < 10%) was detected in 43/62 (69.4%) with a median of 0 (interquartile range 0–5), whereas high Ki-67 labeling index (immunostaining ≥ 10%) was revealed in 19/62 (30.6%) with a median of 20 (interquartile range 12–26). Ki-67 labeling index was significantly associated with tumor grade (P=0.022, Mann-Whitney U Test). There were no significant group differences between Ki-67 labeling index and ER (P=0.43), PR (P=0.7), Her-2/neu (P=0.45), CK5/6 (P=0.29), CK17 (P=0.55), pathologic stage (P=0.4), tumor histology (P=0.99), breast cancer subtypes (P=0.47), tumor size (P=0.16), and age at diagnosis (P=0.6). These results suggested that Ki-67 labeling index correlates with tumor differentiation and not with the tumor size or any other tested marker in Sudanese breast cancers. Thus, Ki-67 labeling index could be considered as a reliable measure of tumor proliferative fraction in Sudan.

Sign in / Sign up

Export Citation Format

Share Document